Liver Transplant denials in California external review

In the California DMHC record, independent physician reviewers decided 16 published external-review cases involving Liver Transplantand overturned the plan’s denial in 37.5%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
16
2002–2025
Overturned
37.5%
6 denials reversed

Conditions behind Liver Transplant denials

What insurers denied — and how those fights ended.
CategoryDecisionsOverturned
Hepatocellular Carcinoma5
0%

What the insurer actually argued

Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
Reason givenDecisionsOverturned
Medical Necessity
The plan said the care wasn’t medically necessary. The most common fight, and the most winnable.
13
30.8%
Experimental/Investigational
The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument.
3
66.7%
Typical time to a decision
4 days
Most land between 3 and 5 days
Handled as urgent
87.5%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for immediate referral for a liver transplant. Early liver transplant in the setting of decompensated alcoholic liver disease, defined as before six months of abstinence from alcohol, is recommended for carefully selected patients with severe medically refractory alcohol associated liver disease who are considered to be at low risk for alcohol relapse post-transplant (Crabb, et al.). Weinberg and colleagues reported that early liver transplantation has been successfully performed in patients with severe alcohol associated hepatitis and prior liver decompensation. This patient presents with a history of alcohol use disorder, alcohol withdrawal seizures, chronic pancreatitis, and alcohol-associated hepatitis.
Medical Necessity · 2022 · IMR MN22-38123
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for a liver transplant. Metastatic carcinoid or neuroendocrine tumor is a rare cancer that is generally not responsive to cytotoxic chemotherapy. This patient has a metastatic neuroendocrine tumor that is currently restricted to the liver. Since this patient's diagnosis, the patient’s medical care has very closely adhered to National Comprehensive Cancer Network (NCCN) guideline recommendations. However, at this time, the patient has exhausted all standard treatment options and is therefore being considered for transplant. A liver transplant is a reasonable next step for this patient who has tried and failed several standard therapies.
Experimental/Investigational · 2025 · IMR EI25-45314

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for liver transplant. Early liver transplant in the setting of decompensated alcoholic liver disease, defined as before six months of abstinence from alcohol, is recommended for carefully selected patients with severe medically refractory alcohol associated liver disease who are considered to be at low risk for alcohol relapse post-transplant (Crabb, et al.). One study reported by Weinberg and colleagues states that early liver transplantation has been successfully performed in well-selected patients with severe alcohol associated hepatitis and prior liver decompensation. This patient presents with a history of alcohol use disorder.
Medical Necessity · 2023 · IMR MN23-38906
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for liver transplant (CPT 47135). This patient has a metastatic neuroendocrine tumor (NET) with involvement of numerous liver metastases, mass in the tail of the pancreas, ascites and possible lymph node involvement. Although this patient has a well-differentiated tumor, the patient also has several risk factors for recurrence or inferior survival including symptomatic tumor, a primary tumor in the pancreas, and greater than 50% involvement of the liver. The patient may have extrahepatic spread as noted by ascites and lymphadenopathy (Moris, et al.). Liver transplantation has been used in the past for patients with isolated metastases to the liver with mixed results. The proposal in this case is for living donor liver transplantation.
Experimental/Investigational · 2021 · IMR EI21-35873

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Liver Transplant, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Denied Liver Transplant? Use the California record to prepare.

Explain my denial — freeStart my appeal · $39